587 related articles for article (PubMed ID: 11049798)
1. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic.
Sundar S; More DK; Singh MK; Singh VP; Sharma S; Makharia A; Kumar PC; Murray HW
Clin Infect Dis; 2000 Oct; 31(4):1104-7. PubMed ID: 11049798
[TBL] [Abstract][Full Text] [Related]
2. Sodium stibogluconate-sensitive visceral leishmaniasis in the non-endemic hilly region of Uttarakhand, India.
Verma SK; Ahmad S; Shirazi N; Kusum A; Kaushik RM; Barthwal SP
Trans R Soc Trop Med Hyg; 2007 Jul; 101(7):730-2. PubMed ID: 17382981
[TBL] [Abstract][Full Text] [Related]
3. Kala-azar in Uttar Pradesh--a study of 66 patients.
Mittal V; Singh VK; Ichhpujani RL
J Commun Dis; 2002 Mar; 34(1):43-9. PubMed ID: 12718341
[TBL] [Abstract][Full Text] [Related]
4. The treatment of visceral leishmaniasis (kala-azar) in India: no obvious signs of long-term success.
Muniaraj M; Paramasivan R; Mariappan T; Arunachalam N; Sinha PK
Trans R Soc Trop Med Hyg; 2012 Dec; 106(12):770-2. PubMed ID: 23102868
[TBL] [Abstract][Full Text] [Related]
5. Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India.
Thakur CP; Narayan S; Ranjan A
Indian J Med Res; 2004 Sep; 120(3):166-72. PubMed ID: 15489554
[TBL] [Abstract][Full Text] [Related]
6. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani.
Lira R; Sundar S; Makharia A; Kenney R; Gam A; Saraiva E; Sacks D
J Infect Dis; 1999 Aug; 180(2):564-7. PubMed ID: 10395884
[TBL] [Abstract][Full Text] [Related]
7. Study of the outbreak of kala-azar epidemic in Bihar.
Thakur CP; Sinha KP; Gupta AK; Kumar SC
J Assoc Physicians India; 1978 Jun; 26(6):511-8. PubMed ID: 721754
[No Abstract] [Full Text] [Related]
8. Drug regimens for visceral leishmaniasis in Mediterranean countries.
Gradoni L; Soteriadou K; Louzir H; Dakkak A; Toz SO; Jaffe C; Dedet JP; Campino L; Cañavate C; Dujardin JC
Trop Med Int Health; 2008 Oct; 13(10):1272-6. PubMed ID: 18764817
[TBL] [Abstract][Full Text] [Related]
9. Visceral leishmaniasis (kala-azar)--the Bihar (India) perspective.
Sinha PK; Ranjan A; Singh VP; Das VN; Pandey K; Kumar N; Verma N; Lal CS; Sur D; Manna B; Bhattacharya SK
J Infect; 2006 Jul; 53(1):60-4. PubMed ID: 16269185
[TBL] [Abstract][Full Text] [Related]
10. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
[TBL] [Abstract][Full Text] [Related]
11. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
Sundar S; Mehta H; Chhabra A; Singh V; Chauhan V; Desjeux P; Rai M
Clin Infect Dis; 2006 Mar; 42(5):608-13. PubMed ID: 16447104
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate.
Chulay JD; Fleckenstein L; Smith DH
Trans R Soc Trop Med Hyg; 1988; 82(1):69-72. PubMed ID: 2845611
[TBL] [Abstract][Full Text] [Related]
13. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
Sundar S; Mehta H; Suresh AV; Singh SP; Rai M; Murray HW
Clin Infect Dis; 2004 Feb; 38(3):377-83. PubMed ID: 14727208
[TBL] [Abstract][Full Text] [Related]
14. Ketoconazole in antimonial unresponsive cases of Kala-azar.
Jha TK; Singh NK; Jha S
J Assoc Physicians India; 1995 May; 43(5):347. PubMed ID: 9081966
[No Abstract] [Full Text] [Related]
15. Clinical risk factors for therapeutic failure in kala-azar patients treated with pentavalent antimonials in Nepal.
Rijal S; Bhandari S; Koirala S; Singh R; Khanal B; Loutan L; Dujardin JC; Boelaert M; Chappuis F
Trans R Soc Trop Med Hyg; 2010 Mar; 104(3):225-9. PubMed ID: 19726065
[TBL] [Abstract][Full Text] [Related]
16. Treatment of kala-azar in India.
Thakur CP
Natl Med J India; 1992; 5(5):203-5. PubMed ID: 1338871
[No Abstract] [Full Text] [Related]
17. Kala-azar in Bihar.
Prasad LS
Indian J Pediatr; 1987; 54(1):103-10. PubMed ID: 3030932
[No Abstract] [Full Text] [Related]
18. Experience with amphotericin B in sodium stibogluconate--unresponsive cases of visceral Leishmaniasis in north Bihar.
Giri OP; Singh AN
J Assoc Physicians India; 1994 Sep; 42(9):690-1. PubMed ID: 7883660
[TBL] [Abstract][Full Text] [Related]
19. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya.
Moore E; O'Flaherty D; Heuvelmans H; Seaman J; Veeken H; de Wit S; Davidson RN
Bull World Health Organ; 2001; 79(5):388-93. PubMed ID: 11417033
[TBL] [Abstract][Full Text] [Related]
20. Antimony-resistant Leishmania donovaniin eastern Sudan: incidence and in vitro correlation.
Abdo MG; Elamin WM; Khalil EA; Mukhtar MM
East Mediterr Health J; 2003 Jul; 9(4):837-43. PubMed ID: 15748080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
